Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

doi:10.1056/NEJMe2012924

Editorial

. 2020 Jun 18;382(25):2462-2464.

doi: 10.1056/NEJMe2012924. Epub 2020 May 1.

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

John A Jarcho¹, Julie R Ingelfinger¹, Mary Beth Hamel¹, Ralph B D'Agostino Sr¹, David P Harrington¹

Affiliations

Affiliation

¹ From the Department of Mathematics and Statistics, Boston University (R.B.D.), the Department of Biostatistics, Harvard T.H. Chan School of Public Health (D.P.H.), and the Department of Data Sciences, Dana-Farber Cancer Institute (D.P.H.) - all in Boston.

PMID: 32356625
PMCID: PMC7224604
DOI: 10.1056/NEJMe2012924

Editorial

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

John A Jarcho et al. N Engl J Med. 2020.

. 2020 Jun 18;382(25):2462-2464.

doi: 10.1056/NEJMe2012924. Epub 2020 May 1.

Authors

John A Jarcho¹, Julie R Ingelfinger¹, Mary Beth Hamel¹, Ralph B D'Agostino Sr¹, David P Harrington¹

Affiliation

¹ From the Department of Mathematics and Statistics, Boston University (R.B.D.), the Department of Biostatistics, Harvard T.H. Chan School of Public Health (D.P.H.), and the Department of Data Sciences, Dana-Farber Cancer Institute (D.P.H.) - all in Boston.

PMID: 32356625
PMCID: PMC7224604
DOI: 10.1056/NEJMe2012924

No abstract available

PubMed Disclaimer

Comment in

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients.
Daoud A, Ali H, Rao V, Rohan V, Soliman K. Daoud A, et al. Ren Fail. 2021 Dec;43(1):1463-1464. doi: 10.1080/0886022X.2021.1994419. Ren Fail. 2021. PMID: 34704916 Free PMC article. No abstract available.

Comment on

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.
Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Mancia G, et al. N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1. N Engl J Med. 2020. PMID: 32356627 Free PMC article.
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.
Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, Hausvater A, Newman JD, Berger JS, Bangalore S, Katz SD, Fishman GI, Kunichoff D, Chen Y, Ogedegbe G, Hochman JS. Reynolds HR, et al. N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1. N Engl J Med. 2020. PMID: 32356628 Free PMC article.

Cited by

Cushing's syndrome and COVID-19.
Attia A, Bertherat J. Attia A, et al. Pituitary. 2024 Nov 14. doi: 10.1007/s11102-024-01466-0. Online ahead of print. Pituitary. 2024. PMID: 39541074 Review.
Epidemiological topology data analysis links severe COVID-19 to RAAS and hyperlipidemia associated metabolic syndrome conditions.
Platt D, Bose A, Rhrissorrakrai K, Levovitz C, Parida L. Platt D, et al. Bioinformatics. 2024 Jun 28;40(Suppl 1):i199-i207. doi: 10.1093/bioinformatics/btae235. Bioinformatics. 2024. PMID: 38940159 Free PMC article.
Association of ACE1 I/D polymorphism and susceptibility to COVID-19 in Egyptian children and adolescents.
Boraey NF, Bebars MA, Wahba AA, Abd El Lateef HM, Attia MA, Elsayed AH, Rashed KA, Sorour EI, Ahmed MF, Abd-Elrehim GAB, Soliman AA, Shehab MMM, Elhindawy EM, Ibraheem AAA, Shehata H, Yousif YM, Hashem MIA, Ahmed AA, Emam AA, Gameil DM, Abdelhady EM, Abdelkhalek K, Morsi WEMA, Selim DM, Razek SA, Ashraf B, Saleh ASE, Eltrawy HH, Alanwar MI, Fouad RA, Omar WE, Nabil RM, Abdelhamed MR, Ibrahim MY, Malek MM, Afify MR, Alharbi MT, Nagshabandi MK, Tarabulsi MK, Qashqary ME, Almoraie LM, Salem HF, Rashad MM, El-Gaaly SAA, El-Deeb NA, Abdallah AM, Fakhreldin AR, Hassouba M, Massoud YM, Attaya MSM, Haridi MK. Boraey NF, et al. Pediatr Res. 2024 Oct;96(5):1347-1354. doi: 10.1038/s41390-023-02982-8. Epub 2024 Jan 4. Pediatr Res. 2024. PMID: 38177248 Free PMC article.
Mitigating secondary disaster triggered by fear of COVID-19: the role of professional medical societies.
Matsuzawa Y, Tsujita K. Matsuzawa Y, et al. Hypertens Res. 2024 Feb;47(2):559-561. doi: 10.1038/s41440-023-01521-6. Epub 2023 Nov 29. Hypertens Res. 2024. PMID: 38030804 No abstract available.
A Meta-Analysis of Remote Ischemic Preconditioning in Lung Surgery and Its Potential Role in COVID-19.
Cahalin LP, Formiga MF, Owens J, Osman BM. Cahalin LP, et al. Physiother Can. 2023 Feb 8;75(1):30-41. doi: 10.3138/ptc-2021-0031. eCollection 2023 Winter. Physiother Can. 2023. PMID: 37250733 Free PMC article.

See all "Cited by" articles

References

1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-280.e8. - PMC - PubMed
1. Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014;16:420-420. - PMC - PubMed
1. Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008;10:410-414. - PMC - PubMed
1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21-e21. - PMC - PubMed
1. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020;38:781-782. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-280.e8. - PMC - PubMed

[2] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2):271-280.e8. - PMC - PubMed

[3] Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014;16:420-420. - PMC - PubMed

[4] Varagic J, Ahmad S, Nagata S, Ferrario CM. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014;16:420-420. - PMC - PubMed

[5] Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008;10:410-414. - PMC - PubMed

[6] Soler MJ, Barrios C, Oliva R, Batlle D. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep 2008;10:410-414. - PMC - PubMed

[7] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21-e21. - PMC - PubMed

[8] Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8(4):e21-e21. - PMC - PubMed

[9] Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020;38:781-782. - PubMed

[10] Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020;38:781-782. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Affiliation

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Authors

Affiliation

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources